Lipoprotein(a)—To test or not to test, not a dilemma but a mandate.

Lipoprotein(a) [Lp(a)] contributes causally to atherosclerosis and aortic stenosis, but testing for this common risk factor has lagged its recognition, a critical gap given the emergence of effective Lp(a) lowering therapies and its high heritability. Eversole et al. present a novel and timely perspective on the human and familial dimensions of elevated Lp(a) as a lived experience that influences patient decisions, anxieties, and hopes.1 This survey-based study moves beyond descriptive statistics to expose systemic gaps in clinical knowledge, highlight testing barriers, and demonstrate how personal experiences shape family cascade screening. These findings serve as a compelling call to action for both the medical and policy communities.